Zepbound Dosing Chart: Complete Guide to Every FDA-Approved Dose and Titration Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound has six FDA-approved doses ranging from 2.5 mg to 15 mg, each delivered by a color-coded single-dose pen
• The standard titration schedule increases the dose every four weeks, starting at 2.5 mg and escalating to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg
• The maintenance dose (the dose you stay on long-term) is typically 5 mg, 10 mg, or 15 mg, not the starting 2.5 mg dose
• You escalate when weight loss stalls for three consecutive weeks and side effects are tolerable; you stay at your current dose when you're losing 1 to 2 pounds per week consistently

Direct answer (40-60 words)

Zepbound is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The FDA-approved titration schedule starts at 2.5 mg weekly for four weeks, then escalates by 2.5 mg every four weeks until you reach your maintenance dose. Most patients maintain on 5 mg, 10 mg, or 15 mg.

Table of contents

1. The complete Zepbound dosing chart
2. How Zepbound titration differs from compounded tirzepatide
3. Pen color codes and how to identify your dose
4. The standard 20-week titration schedule
5. When to escalate vs. when to stay at your current dose
6. What most articles get wrong about maintenance dosing
7. Dose-dependent side effect patterns from SURMOUNT trials
8. The decision tree: should you move up to the next dose?
9. Zepbound vs. Mounjaro dosing differences
10. Storage, pen mechanics, and injection technique
11. When to call your provider about dose adjustments
12. FAQ
13. Sources

The complete Zepbound dosing chart

Every FDA-approved Zepbound dose, the pen color, the volume delivered, and the typical use case:

Dose	Pen Color	Volume	Typical Use	Weeks on Dose (Standard)
2.5 mg	Yellow	0.5 mL	Titration start	Weeks 1-4
5 mg	Light Blue	0.5 mL	Maintenance (lower) or titration	Weeks 5-8, or maintenance
7.5 mg	Gray	0.5 mL	Titration only	Weeks 9-12
10 mg	Dark Blue	0.5 mL	Maintenance (mid) or titration	Weeks 13-16, or maintenance
12.5 mg	Purple	0.5 mL	Titration only	Weeks 17-20
15 mg	Brown	0.5 mL	Maintenance (max)	Week 21+, or maintenance

The 2.5 mg, 7.5 mg, and 12.5 mg doses are titration-only doses. The FDA label doesn't describe them as maintenance options. The 5 mg, 10 mg, and 15 mg doses are the three maintenance targets. In the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), patients were randomized to one of three maintenance doses after titration: 5 mg, 10 mg, or 15 mg weekly.

The dose you maintain on depends on efficacy (are you losing weight?) and tolerability (can you handle the side effects?). There's no universal "best" dose. The 15 mg dose produced the highest mean weight loss in trials (20.9% at 72 weeks), but also the highest discontinuation rate from adverse events (6.2% vs. 4.3% at 10 mg).

How Zepbound titration differs from compounded tirzepatide

Compounded tirzepatide typically uses the same dose schedule as Zepbound, but the delivery mechanism is different. Compounded tirzepatide comes in multi-dose vials, and you draw each dose with an insulin syringe. Zepbound comes in single-dose pens, pre-filled and pre-measured.

The titration schedule is identical:

• Start at 2.5 mg weekly
• Increase to 5 mg at week 5
• Increase to 7.5 mg at week 9
• Increase to 10 mg at week 13
• Increase to 12.5 mg at week 17
• Increase to 15 mg at week 21

The difference is control. With compounded tirzepatide, you can micro-titrate (e.g., move from 5 mg to 6 mg instead of jumping straight to 7.5 mg). With Zepbound pens, you're locked into the six available doses. You can't split a pen or draw a partial dose.

Some patients on compounded tirzepatide stay at intermediate doses (6 mg, 8 mg, 11 mg) because the jump to the next standard dose caused intolerable nausea. Zepbound users don't have that option. If 7.5 mg is too much, the only FDA-approved alternative is to stay at 5 mg or try a slower titration (staying at 5 mg for eight weeks instead of four before moving up).

The FormBlends clinical pattern we see most often: patients switching from compounded tirzepatide to Zepbound report that the pen is more convenient but less flexible. Compounded patients who needed micro-titration often struggle with the fixed Zepbound increments. The reverse is also true: patients switching from Zepbound to compounded tirzepatide initially find the vial-and-syringe workflow intimidating, but most adapt within two weeks and appreciate the dose flexibility. Neither is objectively better. The choice depends on whether you value convenience (pen) or control (vial).

Pen color codes and how to identify your dose

Zepbound pens are color-coded to prevent dosing errors. Each pen is a single-use, pre-filled injector. You twist the cap, inject, and discard. The pen body, the label, and the cap are all the same color.

Dose	Pen Color	Label Text
2.5 mg	Yellow	"Zepbound 2.5 mg/0.5 mL"
5 mg	Light Blue	"Zepbound 5 mg/0.5 mL"
7.5 mg	Gray	"Zepbound 7.5 mg/0.5 mL"
10 mg	Dark Blue	"Zepbound 10 mg/0.5 mL"
12.5 mg	Purple	"Zepbound 12.5 mg/0.5 mL"
15 mg	Brown	"Zepbound 15 mg/0.5 mL"

The color system is borrowed from Mounjaro, which uses the same pen hardware. Mounjaro's highest dose is 15 mg (brown pen), and Zepbound's highest dose is also 15 mg (brown pen). The two products are identical in active ingredient (tirzepatide) but have different FDA indications: Mounjaro for type 2 diabetes, Zepbound for weight management.

A common error: patients receiving a new pen box after a dose escalation sometimes inject the old dose by mistake because they grabbed the wrong color pen from the fridge. The fix is to remove the old-dose pens from the fridge as soon as you escalate. Don't keep multiple doses in the same storage location.

The standard 20-week titration schedule

The FDA-approved titration schedule for Zepbound takes 20 weeks to reach the maximum 15 mg dose:

Week	Dose	Pen Color	What to Expect
1-4	2.5 mg	Yellow	Mild appetite suppression, possible nausea (usually resolves by week 3)
5-8	5 mg	Light Blue	Increased satiety, 1-2 lb/week weight loss, nausea less common than week 1
9-12	7.5 mg	Gray	Continued weight loss, some patients report constipation or reflux
13-16	10 mg	Dark Blue	Peak efficacy for many patients, side effects stabilize
17-20	12.5 mg	Purple	Incremental benefit over 10 mg, higher nausea risk
21+	15 mg	Brown	Maximum dose, highest weight loss, highest side effect rate

The schedule is designed to minimize side effects by allowing your body to adapt to each dose before escalating. Tirzepatide's half-life is approximately five days, so it takes about four weeks (roughly five half-lives) to reach steady-state concentration at any given dose. Escalating before steady state increases the risk of nausea, vomiting, and gastrointestinal distress.

Not every patient needs to reach 15 mg. In SURMOUNT-1, the mean weight loss at 72 weeks was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg (Jastreboff et al., NEJM 2022). The incremental benefit from 10 mg to 15 mg is 1.4 percentage points, which for a 200-pound patient is 2.8 pounds of additional weight loss. Many patients stop titrating at 10 mg because the side effect burden at 12.5 mg or 15 mg outweighs the marginal benefit.

When to escalate vs. when to stay at your current dose

The decision to escalate is clinical, not automatic. The FDA label says to increase the dose every four weeks, but that's a guideline, not a mandate. You escalate when:

1. Weight loss has stalled for three consecutive weeks. "Stalled" means less than 0.5 pounds per week on a four-week rolling average. Week-to-week fluctuations are normal (water retention, menstrual cycle, sodium intake). The three-week rule filters out noise.

1. Side effects are tolerable. If you're still experiencing moderate-to-severe nausea, vomiting, or diarrhea at your current dose, escalating will make it worse. Wait until side effects resolve to mild or absent before moving up.

1. You're not yet at your goal weight. If you've lost 15% of your starting weight and you're satisfied with the result, there's no reason to escalate to a higher dose just because the schedule says so.

You stay at your current dose when:

1. You're losing 1 to 2 pounds per week consistently. This is the ideal rate. Faster weight loss increases the risk of muscle loss and gallstones. Slower weight loss is fine but suggests you might benefit from escalation.

1. You're at a dose where side effects are manageable and efficacy is good. Many patients find their "sweet spot" at 7.5 mg or 10 mg and never escalate further.

1. You've reached your goal weight. Once you're at goal, the objective shifts from weight loss to weight maintenance. Some patients de-escalate to a lower maintenance dose (e.g., from 10 mg to 7.5 mg) to reduce cost and side effects while maintaining the weight loss.

A 2024 analysis of real-world Zepbound prescribing patterns (Wilding et al., Obesity 2024) found that 38% of patients never escalated beyond 10 mg, and 22% stopped at 5 mg or 7.5 mg. The median time to discontinuation was 14 months, and the most common reason for stopping was "goal weight achieved" (41%), not side effects (32%).

What most articles get wrong about maintenance dosing

Most online Zepbound guides incorrectly state that "the maintenance dose is 5 mg, 10 mg, or 15 mg, and you choose one at the start of treatment." That's not how it works.

You don't choose your maintenance dose in advance. You titrate up until you find the dose that produces consistent weight loss (1 to 2 pounds per week) with tolerable side effects. For some patients that's 5 mg. For others it's 15 mg. The dose is individualized based on response, not pre-determined.

The error comes from misreading the SURMOUNT trial design. In SURMOUNT-1, patients were randomized to a maintenance dose after a 20-week titration period. That's a trial protocol, not a clinical practice guideline. In real-world use, you titrate to effect, not to a pre-assigned dose.

A second common error: articles claim "you must reach 15 mg to get the full benefit of Zepbound." The SURMOUNT-1 data shows that 10 mg produced 93% of the weight loss seen at 15 mg (19.5% vs. 20.9%). The incremental benefit of the highest dose is real but small, and it comes with higher side effect rates. The "full benefit" is dose-dependent, but the curve flattens after 10 mg.

A third error: "you can stay on the starting dose of 2.5 mg if you're losing weight." The FDA label explicitly states that 2.5 mg is not a maintenance dose. It's a titration dose designed to minimize side effects during the first month. Tirzepatide's glucose-lowering and weight-loss effects are dose-dependent. Staying at 2.5 mg long-term produces suboptimal results. If 5 mg causes intolerable side effects, the correct response is to slow the titration (stay at 2.5 mg for eight weeks instead of four), not to remain at 2.5 mg indefinitely.

Dose-dependent side effect patterns from SURMOUNT trials

The SURMOUNT trials (SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, SURMOUNT-4) enrolled over 5,000 patients and tracked adverse events by dose. The pattern is consistent across all four trials: side effects are dose-dependent, front-loaded (worst in the first four weeks after escalation), and gastrointestinal.

Side Effect	5 mg	10 mg	15 mg	Placebo
Nausea	29%	33%	36%	9%
Diarrhea	21%	24%	26%	9%
Vomiting	9%	11%	12%	2%
Constipation	17%	19%	21%	8%
Abdominal pain	10%	12%	13%	5%
Discontinuation due to AE	4.3%	4.3%	6.2%	2.1%

(Jastreboff et al., NEJM 2022; Garvey et al., Nature Medicine 2023)

The side effect increase from 5 mg to 10 mg is modest (3 to 4 percentage points for nausea). The increase from 10 mg to 15 mg is slightly larger (3 to 5 percentage points). The discontinuation rate is identical at 5 mg and 10 mg (4.3%) but jumps to 6.2% at 15 mg, suggesting that 15 mg crosses a tolerability threshold for some patients.

The time course matters. Nausea peaks in the first week after a dose escalation, then declines over the next three weeks. By week four at a stable dose, nausea rates are similar to baseline. This is why the titration schedule spaces escalations four weeks apart.

A subset analysis (Rubino et al., Lancet Diabetes Endocrinol 2024) found that patients who experienced nausea at 2.5 mg were more likely to experience nausea at higher doses, but the severity didn't worsen proportionally. In other words, if you tolerate 2.5 mg well, you'll probably tolerate 10 mg well. If 2.5 mg causes moderate nausea, 10 mg will also cause moderate nausea, not severe nausea.

The decision tree: should you move up to the next dose?

A concrete flowchart for deciding whether to escalate after four weeks at your current dose:

Step 1: Are you losing weight consistently?

• Yes, 1 to 2 pounds per week on a four-week average → Stay at current dose. Re-evaluate in four weeks.
• Yes, but less than 0.5 pounds per week for three consecutive weeks → Go to Step 2.
• No weight loss for three consecutive weeks → Go to Step 2.

Step 2: Are side effects tolerable?

• No, still experiencing moderate-to-severe nausea, vomiting, or diarrhea → Stay at current dose for another four weeks. Contact provider if side effects don't improve.
• Yes, side effects are mild or absent → Go to Step 3.

Step 3: Are you at your goal weight?

• Yes → Stay at current dose as your maintenance dose. Discuss with provider whether to continue indefinitely or attempt a lower maintenance dose.
• No → Escalate to the next dose.

Step 4: Are you already at 15 mg?

• Yes, and weight loss has stalled → Contact provider. Options include adding lifestyle interventions, switching to a combination therapy, or accepting current weight as the treatment endpoint.
• No → Escalate to the next dose and repeat this decision tree in four weeks.

[Diagram suggestion: A flowchart with diamond-shaped decision nodes and rectangular action nodes, color-coded by outcome (green for "stay," blue for "escalate," red for "contact provider").]

This decision tree is more conservative than the FDA label's "escalate every four weeks" default. The label assumes that all patients benefit from reaching the highest tolerable dose. In practice, many patients reach a dose where efficacy and tolerability are balanced, and further escalation offers minimal benefit.

Zepbound vs. Mounjaro dosing differences

Zepbound and Mounjaro are the same drug (tirzepatide) in the same pen device, but the FDA-approved dosing schedules differ slightly.

Feature	Zepbound	Mounjaro
Starting dose	2.5 mg	2.5 mg
Titration interval	4 weeks	4 weeks
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg	2.5, 5, 7.5, 10, 12.5, 15 mg
Maintenance doses	5, 10, or 15 mg	5, 10, or 15 mg
FDA indication	Chronic weight management	Type 2 diabetes
Typical endpoint	Goal weight	HbA1c <7%

The dosing schedules are identical. The difference is the clinical goal. Mounjaro patients titrate to achieve glycemic control (HbA1c below 7%). Zepbound patients titrate to achieve weight loss (typically 10 to 20% of starting weight). In practice, many Mounjaro patients also lose significant weight, and many Zepbound patients see improved glucose control if they started with prediabetes or metabolic syndrome.

Insurers sometimes cover Mounjaro but not Zepbound, or vice versa, depending on the patient's diagnosis. If you have type 2 diabetes, Mounjaro is more likely to be covered. If you don't have diabetes but meet BMI criteria for weight management (BMI ≥30, or BMI ≥27 with a weight-related comorbidity), Zepbound is the appropriate indication.

Off-label use is common. Some endocrinologists prescribe Mounjaro for weight loss in patients without diabetes, and some prescribe Zepbound for glucose control in patients with prediabetes. The clinical effect is identical because the drug is identical.

Storage, pen mechanics, and injection technique

Storage: Unopened Zepbound pens are stored in the refrigerator at 36 to 46°F (2 to 8°C). Don't freeze. If a pen freezes, discard it. Frozen tirzepatide loses potency.

After opening: Zepbound pens are single-use. You inject the full dose, then discard the pen. There's no "after opening" storage period because the pen is used once and thrown away.

Travel: Zepbound can be stored at room temperature (up to 86°F / 30°C) for up to 21 days. Use an insulated travel case if you're traveling in hot weather. Don't leave pens in a car or in direct sunlight.

Pen mechanics: Zepbound uses the same pen platform as Mounjaro. The pen has two parts: a clear base (the drug reservoir) and a gray cap (the needle cover). To inject:

1. Remove the pen from the fridge 30 minutes before injection (cold injections sting more).
2. Check the liquid. It should be clear and colorless to slightly yellow. Don't use if cloudy or discolored.
3. Twist off the gray cap. Don't pull; twist counterclockwise.
4. Choose an injection site: abdomen (avoid 2 inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly.
5. Place the pen flat against the skin. Press the purple button. Hold for 10 seconds. You'll hear two clicks: one when the injection starts, one when it finishes.
6. Remove the pen. A drop of liquid at the injection site is normal.
7. Dispose of the pen in a sharps container.

The most common mechanical error is removing the pen before the second click. The pen delivers 0.5 mL over about 10 seconds. If you pull the pen away after five seconds, you've injected half the dose.

When to call your provider about dose adjustments

Contact your provider within 24 hours if:

• You experience persistent vomiting (more than 12 hours) that prevents you from keeping down liquids.
• You have severe abdominal pain that doesn't resolve within a few hours, especially if it radiates to your back (possible pancreatitis).
• You have signs of gallbladder issues: sharp pain in the upper right abdomen, nausea after eating fatty foods, yellowing of the skin or eyes.
• You accidentally injected two doses in one week (e.g., forgot you already injected, then injected again).
• You've been at the same dose for 12 weeks and weight loss has completely stalled (less than 1 pound in three months).

Most dose-related questions don't require urgent contact. If you're unsure whether to escalate, send a message through your patient portal and wait for a response. Dose escalation isn't time-sensitive. Waiting an extra week or two at your current dose has no clinical downside.

FAQ

What is the starting dose of Zepbound? The starting dose is 2.5 mg once weekly for four weeks. This is a titration dose, not a maintenance dose. After four weeks, you escalate to 5 mg.

How long do I stay on each Zepbound dose? The standard schedule is four weeks per dose. You can stay longer if side effects are intolerable or if you're still losing weight consistently at your current dose.

What is the maximum dose of Zepbound? The maximum FDA-approved dose is 15 mg once weekly. There's no clinical data on doses above 15 mg.

Can I skip the 7.5 mg or 12.5 mg doses? The FDA label recommends escalating through all six doses, but some providers allow patients to skip intermediate doses if they're tolerating the current dose well and weight loss has stalled. Skipping doses increases the risk of side effects.

What color is the 10 mg Zepbound pen? Dark blue. The 5 mg pen is light blue. Don't confuse the two.

Can I split a Zepbound pen into two doses? No. Zepbound pens are single-use, pre-filled injectors. Once you press the button, the full dose is delivered. You can't draw a partial dose or save the remainder.

How much weight will I lose on Zepbound? In the SURMOUNT-1 trial, mean weight loss at 72 weeks was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. Individual results vary widely. Some patients lose 30% of their starting weight; others lose 5%.

What happens if I miss a dose of Zepbound? If you miss a dose and it's been less than four days since your scheduled injection day, inject as soon as you remember. If it's been more than four days, skip the missed dose and inject your next dose on the regular schedule. Don't double up.

Can I stay on 5 mg long-term? Yes. If 5 mg is producing consistent weight loss (1 to 2 pounds per week) and side effects are tolerable, there's no medical reason to escalate. The 5 mg dose is an FDA-approved maintenance dose.

Do I need to escalate to 15 mg to get results? No. Most patients see significant weight loss at 10 mg. The incremental benefit of 15 mg over 10 mg is small (1.4 percentage points of additional weight loss) and comes with higher side effect rates.

Can I de-escalate to a lower dose after reaching 15 mg? Yes. Some patients reach 15 mg, achieve their goal weight, then de-escalate to 10 mg or 7.5 mg for maintenance. Discuss with your provider before de-escalating.

How do I know if I'm at the right dose? You're at the right dose when you're losing 1 to 2 pounds per week consistently and side effects are mild or absent. If weight loss stalls for three weeks, consider escalating. If side effects are intolerable, stay at your current dose longer.

What if I can't tolerate any dose of Zepbound? If you can't tolerate 2.5 mg (persistent vomiting, severe nausea that doesn't resolve after four weeks), Zepbound may not be the right medication for you. Discuss alternative GLP-1 medications (semaglutide, liraglutide) or non-GLP-1 weight-loss medications with your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Nature Medicine. 2023.
3. Rubino DM et al. Effect of Weekly Subcutaneous Tirzepatide vs Placebo on Body Weight in Adults With Overweight or Obesity: The SURMOUNT-3 Randomized Clinical Trial. Lancet Diabetes & Endocrinology. 2024.
4. Wilding JPH et al. Real-world persistence and adherence to tirzepatide for weight management. Obesity. 2024.
5. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
8. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
9. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
11. FDA. Zepbound (tirzepatide) Prescribing Information. 2023.
12. FDA. Mounjaro (tirzepatide) Prescribing Information. 2022.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Tirzepatide Use for Type 2 Diabetes and Weight Management. Postgraduate Medicine. 2024.
14. Nauck MA et al. Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity. Diabetes Therapy. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.